← Browse by Condition
Medical Condition
peripheral t cell lymphoma
Total Trials
8
Recruiting Now
8
Trial Phases
Phase 2, Phase 3, Phase 2, Phase 3
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — peripheral t cell lymphoma Clinical Trials
How many clinical trials are currently recruiting for peripheral t cell lymphoma?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for peripheral t cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for peripheral t cell lymphoma?
peripheral t cell lymphoma research spans Phase 1 (2 trials), Phase 2 (5 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a peripheral t cell lymphoma clinical trial?
Eligibility criteria for peripheral t cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 5
Phase 3 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07389616 Phase 2, Phase 3
Recruiting
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Enrollment
40 pts
Location
China
Sponsor
Shanghai General Hospital, Sha...
NCT05958719 Phase 2
Recruiting
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Enrollment
37 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
NCT06131801
Recruiting
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Enrollment
30 pts
Location
United States
Sponsor
Children's Hospital Medical Ce...
NCT06072131 Phase 3
Recruiting
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Enrollment
504 pts
Location
United States, Canad...
Sponsor
Acrotech Biopharma Inc.
NCT06433362 Phase 2
Recruiting
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
Enrollment
115 pts
Location
China
Sponsor
Tianjin Medical University Can...
NCT04045470
Recruiting
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Enrollment
20 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
NCT04390737 Phase 1, Phase 2
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
Enrollment
254 pts
Location
United States, China
Sponsor
Haihe Biopharma Co., Ltd.
NCT04068597 Phase 1, Phase 2
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Enrollment
250 pts
Location
United States, Franc...
Sponsor
CellCentric Ltd.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology